Platelet reactive alloantibodies responsible for immune thrombocytopenia in Malay population

  • Mohd I. Armawai Division of Immunohematology, National Blood Centre of Malaysia
  • Afifah Hassan Division of Immunohematology, National Blood Centre of Malaysia
  • Hevi Wihadmadyatami Institute for Clinical Immunology and Transfusion Medicine, Justus Liebig University, Giessen
  • Sentot Santoso Institute for Clinical Immunology and Transfusion Medicine, Justus Liebig University, Giessen
Keywords: alloimmune thrombocytopenia, transfusion


Background: Alloantibodies against human platelet alloantigens (HPAs) are responsible for the development of platelet transfusion refractoriness (PTR) in patients receiving random platelets and bleeding disorder in babies with fetal neonatal alloimmune thrombocytopenia (FNAIT). Recently, our results based on the analysis of the allelic distribution of HPAs indicated that immunization may occur among Malay. In this study, we sought to analyze the frequencies of platelet reactive alloantibodies responsible for FNAIT and PTR in Malaysia.

Methods: Sera from suspected FNAIT (n = 295) and PTR (n = 74) were collected in five years period (2008-2013) and tested for the presence of platelet reactive antibodies by the use of antigen capture assay.

Results: In 5/74 (5.41%) platelet specific antibodies against HPA-2b (n = 1), HPA-5a (n = 1), HPA-5b (n = 1), HPA-15b (n = 2) could be identified in our PTR cohort. In FNAIT cohort, platelet specific alloantibodies could be detected in 18 sera (6.10%) consisting anti-HPA-1a (n = 1), anti-HPA-3a (n = 3), anti-HPA-5a (n = 6), anti-HPA-5b (n = 6), anti-HPA-15a (n = 1), and anti-HPA-15b (n = 1).

Conclusion: Our study indicates that anti-HPA-3, -HPA-5 and -HPA-15 antibodies seems to be the most platelet specific antibodies involved in FNAIT and PTR cases in Malaysian population. Since similar HPA allelic distribution among Malaysian and Indonesian populations have been observed, immunization against these three HPA systems are expected to be the most potential risk of alloimmune mediated platelet disorders in Indonesia.


Metcalfe P, Watkins NA, Ouwehand WH, Kaplan C, Newman P, Kekomaki R, et al. Nomenclature of human platelet antigens. Vox Sang. 2003;85(3):240-5.

Juji T, Watanabe Y, Ishikawa Y, Fujiwara K, Tonami H, Tanaka H, et al. Human platelet alloantigen (HPA)-5a/b mismatch decreases disease-free survival in unrelated bone marrow transplantation. Tissue Antigens. 1999;54(3):229-34.

Mueller-Eckhardt C, Grubert A, Weisheit M, Mueller-Eckhardt G, Kiefel V, Kroll H, et al. 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet. 1989;333(8634):363-6.

Kiefel V, Konig C, Kroll H, Santoso S. Platelet antibodies in transfused patients. Transfusion. 2001;41(6):766-70.

Kiefel V, Schönberner-Richter I, Schilf K. Anti-HPA-1a in a case of post-transfusion purpura: binding to antigen-negative platelets detected by adsorption/elution. Transfusion Med. 2005;15(3):243-7.

Veldhuisen B, Porcelijn L, Ellen van der Schoot C, de Haas M. Molecular typing of human platelet and neutrophil antigens (HPA and HNA). Transfus Apher Sci. 2014;50(2):189-99.

Tan J.Y, Lian L.H, Nadarajan V.S. Genetic polymorphisms of human platelet antigen-1 to -6 and -15 in the Malaysian population. Blood Transfusion. 2012;10(3):368-76.

Asmarinah, Dharma R, Ritchie N.K, Rahayu S, Putricahya E, Santoso S. Human platelet-specific antigen frequencies in Indonesian population. Transfus Med. 2013;23(4):250-3.

Kiefel V, Santoso S, Weisheit M, Müeller-Eckhardt C. Monoclonal antibody--specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. Blood. 1987;70(6):1722-6.

Campbell K, Rishi K, Howkins G, Gilby D, Mushens R, Ghevaert C, et al. A modified fast MAIPA for the detection of HPA antibodies: a multi-centre evaluation of a rapid monoclonal antibody specific immobilisation of platelet antigen (MAIPA) assay. Vox Sang. 2007;93: 289-97.

Saito S, Ota M, Komatsu Y, Ota S, Aoki S, Koike K, et al. Serologic analysis of three cases of neonatal alloimmune thrombocytopenia associated with HLA antibodies. Transfusion. 2003;43(7):908-17.

Tsuno NH, Matsuhashi M, Iino J, Nagura Y, Okazaki H, Santoso S. The importance of platelet antigens and antibodies in immune-mediated thrombocytopenia. ISBT Science Series. 2014;9(1):104-11.

Sidiropoulos D, Straume B. The treatment of neonatal isoimmune thrombocytopenia with intravenous immunoglobulin. Blut. 1984;48:383-56.

Roberts I, Stanworth S, Murray NA. Thrombocytopenia in the neonates. Blood reviews. 2008;22(4):173-86.

Warkentin TE, Smith JW, Hayward CP, Ali AM, Kelton JG. Thrombocytopenia caused by passive transfusion of anti-glycoprotein Ia/IIa alloantibody (anti-HPA-5b). Blood. 1992;79(9):2480-4.

Ertel K, Al-Tawil M, Santoso S, Kroll H. Relevance of the HPA-15 (Gov) polymorphism on CD109 in alloimmune thrombocytopenia syndromes. Transfusion. 2005;45(3):366-73.

Socher I, Kroll H, Jorks S, Santoso S, Sachs UJH. Heparin-independent activation of platelets by heparin-induced thrombocytopenia antibodies: a common occurance. J Thromb and Haemost. 2008;6(1):197-200.

Matsuhashi M, Tsuno NH, Sone S, Mishima Y, Nagura Y, Watanabe-Okochi N, et al. The role of alloantibodies against human platelet antigen-15 in multiply platelet transfused patients. Transfusion. 2014;54(4):1093-9.

How to Cite
Armawai MI, Hassan A, Wihadmadyatami H, Santoso S. Platelet reactive alloantibodies responsible for immune thrombocytopenia in Malay population. Med J Indones [Internet]. 2014Oct.15 [cited 2024Feb.28];23(3):158-62. Available from:
Clinical Research